ArticleMolecular pharmaceutics2022
High-Contrast Detection of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery.
Article in Molecular pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- A Comparative Study on the Effect of Near-Infrared Fluorescent Dyes on the Pharmacokinetic Behavior of Nanobody-Based Tracers for In Vivo Imaging.Journal of medicinal chemistry · 2025Article
- ASO Author Reflections: Risks and Benefits of Robotic Central Pancreatectomy.Annals of surgical oncology · 2025Article
- Novel FAP-Targeted Heptamethine Cyanines for NIRF Imaging Applications.Molecular pharmaceutics · 2025Article
- Benzyl Ammonium Carbamates Undergo Two-Step Linker Cleavage and Improve the Properties of Antibody Conjugates.Angewandte Chemie (International ed. in English) · 2025Article
- Tissue-seeking dyes for in vivo applications.Smart molecules : open access · 2024Review
- eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors.EJNMMI radiopharmacy and chemistry · 2024Article
- Enhancing precision in colorectal cancer surgery: development of an LGR5-targeting RSPO1 peptide mimetic as a contrast agent for intraoperative fluorescence molecular imaging.Cell cycle (Georgetown, Tex.) · 2024Article
- Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide.Journal of medicinal chemistry · 2024Article
- Method To Diversify Cyanine Chromophore Functionality Enables Improved Biomolecule Tracking and Intracellular Imaging.Journal of the American Chemical Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
Dye design can influence the ability of fluorescently labeled imaging agents to generate tumor contrast and has become an area of significant interest in the field of fluorescence-guided surgery (FGS). Here, we show that the charge-balanced near-infrared fluorescent (NIRF) dye FNIR-Tag enhances the imaging properties of a fluorescently labeled somatostatin analogue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.